Davalintide
A second-generation copy of the gut-and-pancreas hormone amylin, engineered to curb appetite longer and more strongly; it reached a phase 2 obesity trial and was then shelved
Amylin is a hormone released with insulin after a meal; it tells the brain the body is full, slows the stomach's emptying and holds back glucagon, so it curbs appetite and steadies blood sugar. Its injectable copy pramlintide is used in diabetes but is short-acting. Davalintide, coded AC-2307, is a second-generation amylin-mimetic peptide built on a calcitonin backbone to bind the amylin receptors more tightly and act far longer. In animals it suppressed food intake and produced durable, fat-specific weight loss well beyond native amylin. It was taken into a phase 2 obesity trial, but development was discontinued and no results were published in people; it is not an approved medicine.
No dosing data yet Details ↓
Recommended Dosing
No dosing data yet
This page has no dosing data yet.
What is it?
After a meal the pancreas releases amylin alongside insulin. Amylin acts on the hindbrain to signal fullness, slows how fast the stomach empties and suppresses the release of glucagon, the hormone that raises blood sugar. Together these actions curb appetite and smooth the rise in glucose after eating, which is why an amylin copy, pramlintide, is used with insulin in diabetes. Pramlintide's drawback is that it is short-acting and has to be injected at each meal.
Davalintide, coded AC-2307, was Amylin Pharmaceuticals' attempt at a sturdier, longer-acting amylin. Rather than a small tweak of the human hormone, it is a chimeric peptide: a salmon-calcitonin backbone (calcitonin and amylin are structural cousins that share receptors) carrying amylin-like changes, so it binds the amylin, calcitonin and CGRP receptors with high affinity. The design aim was a molecule that switched on the same satiety machinery as amylin but held the signal on for far longer.
In rodents it did exactly that. A single dose suppressed feeding for about 23 hours against roughly 6 for amylin, and sustained infusion produced weight loss that was dose-dependent, durable over weeks, fat-specific and lean-sparing, with metabolic rate preserved and a shift in food choice away from fatty chow. Follow-up work showed matching glucoregulatory effects — slowed gastric emptying and suppressed glucagon — and traced the prolonged action partly to the peptide staying bound to its brain receptor rather than to a long time in the blood. These properties also made davalintide a favoured partner in experimental two-in-one "phybrid" peptides that joined it to a GLP-1 agonist for added weight loss.
The human record is where it stops. A phase 2, randomized, placebo-controlled dose-ranging trial of subcutaneous AC-2307 for body weight enrolled 273 overweight or obese people and completed in 2009 (NCT00785408), but its results were never posted to the registry or published in a journal, and the programme was discontinued. No study of davalintide in people is published in PubMed, so its whole published record is preclinical — the animal pharmacology, the receptor and metabolite work, and the hybrid-peptide experiments described on this page.
Davalintide belongs to the amylin lineage that now runs through pramlintide to the modern long-acting analogue cagrilintide and the amylin agonists in late-stage obesity trials. It is a step on that path rather than a destination: an investigational compound, not a medicine, and nothing here is a dose to use.
At a Glance
Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.
Mechanism of Action
Davalintide is an engineered, long-acting amylin. It switches on the same appetite- and glucose-controlling receptors as the natural hormone, but binds them more tightly and holds the signal on far longer.
Amylin receptors and satiety
Davalintide is a high-affinity agonist at the amylin receptors (the calcitonin receptor paired with RAMP proteins) in the hindbrain, driving the fullness signal, slowed gastric emptying and glucagon suppression that curb appetite and steady glucose (PMIDs 19935749, 21733060).
Slow receptor release for a longer action
Though cleared from the blood about as fast as amylin, davalintide stays bound to its brain receptor far longer, which is why one dose suppresses feeding for roughly a day rather than hours (PMID 21733060) — a pharmacodynamic, not pharmacokinetic, advantage.
Fat-specific, lean-sparing weight loss
In rodents its weight loss was dose-dependent and durable, came from fat rather than lean mass, and preserved metabolic rate (PMID 19935749), the profile that made it a building block for experimental amylin + GLP-1 combination peptides.
Published Research
These are studies of davalintide read from their PubMed abstracts on November 5, 2026. The record is entirely preclinical: rodent pharmacology showing a longer, stronger amylin action, the glucoregulatory follow-up, a head-to-head against a dual amylin/calcitonin agonist, and a bioanalytical paper on the drug and its active metabolite. No human study of davalintide is indexed in PubMed, although a phase 2 obesity trial completed.
A longer, stronger amylin in rodents
The first full pharmacology of davalintide (AC2307). It bound the amylin, calcitonin and CGRP receptors with high affinity and, compared with native amylin, suppressed feeding more strongly and for far longer (about 23 versus 6 hours). Infused into rats, it produced dose-dependent, durable weight loss over eight weeks that was fat-specific and lean-sparing, with metabolic rate maintained and a shift away from high-fat food, acting through the same brain pathways as amylin.
Glucose effects and prolonged action
In rats, davalintide slowed gastric emptying as potently as amylin but for much longer (8 hours), suppressed the glucagon rise after an arginine challenge, and lowered glucose after an oral glucose load during two-week infusion. Its blood half-life was short (about 26 minutes), like amylin's, so the extended effect was traced to the peptide staying bound to its brain receptor rather than lingering in plasma.
Benchmarked against a dual agonist
A dual amylin and calcitonin receptor agonist (KBP-088) was compared head-to-head with davalintide in high-fat-fed rats dosed daily for 62 days. KBP-088's longer receptor activation gave greater, more sustained weight loss (about 16 percent) and better glucose tolerance than davalintide, using davalintide as the amylinomimetic benchmark for the class.
Measuring the drug and its active metabolite
A laboratory method study. Davalintide is rapidly trimmed in the body, losing its N-terminal lysine to form an active des-lysine metabolite. The authors built a mass-spectrometry assay in beagle and rat plasma that could tell the drug and metabolite apart, which an antibody assay could not, documenting that davalintide circulates together with an active breakdown product.
Side Effects & Contraindications
Reported Side Effects
There is no published human safety profile and no approved label; the points below come from the preclinical record and the amylin class.
Contraindications & Cautions
Davalintide has no label and no approved use. These points come from the molecule and its status.
Legal Status
Davalintide is an investigational compound that was never approved in any country and is not marketed.
Frequently Asked Questions
?What is davalintide?
An experimental weight-loss peptide, coded AC-2307, that is a second-generation, longer-acting copy of the appetite hormone amylin. It was developed by Amylin Pharmaceuticals and tested for obesity.
?Did it work?
In animals it strongly and durably reduced food intake and body weight, well beyond native amylin (PMID 19935749). In people, a phase 2 obesity trial of 273 subjects completed in 2009 but its results were never published and the programme was discontinued, so its human effect is not established.
?How is it different from pramlintide and cagrilintide?
All act on the amylin receptors. Pramlintide is a short-acting amylin copy used in diabetes; cagrilintide is a modern long-acting amylin analogue in obesity trials. Davalintide was an earlier attempt at a longer-acting amylin, now discontinued.
?Is it approved or available to buy?
No. There is no FDA application or label as of November 5, 2026 and no approval anywhere, and it is not sold as a medicine. Grey Peptides lists no sellers and recommends no source; this page records the published science.
References
- [animal] Mack CM, et al. "Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight." Int J Obes (Lond), 2010;34(2):385-95. PMID: 19935749.
- [animal] Mack CM, et al. "Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide." Diabetes Obes Metab, 2011;13(12):1105-13. PMID: 21733060.
- [animal] Gydesen S, et al. "KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight." Am J Physiol Endocrinol Metab, 2016;310(10):E821-7. PMID: 26908506.
- [mechanism] Wang Y, et al. "Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS." Bioanalysis, 2012;4(17):2141-52. PMID: 23013396.
- [other] FDA Global Substance Registration System, Davalintide, UNII 668U999F9T (INN 9124, CAS 863919-85-1, PubChem 71587842, DrugBank DB14956; code AC-2307), read November 5, 2026: a 32-amino-acid chimeric amylinomimetic peptide built on a salmon calcitonin-1 backbone with amylin-like substitutions (KCNTATCVLGRLSNELHRLNTYPRTNTGSNTY). https://gsrs.ncats.nih.gov/ginas/app/beta/substances/668U999F9T
- [other] ChEMBL molecule CHEMBL2105635 (DAVALINTIDE), read November 5, 2026: synonyms Davalintide, AC-2307, AC2307; highest clinical phase recorded 2. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105635/
- [other] US FDA, Drugs@FDA and the drug label endpoint (openFDA), searched November 5, 2026: no application and no label record for davalintide. It has an FDA substance record (UNII 668U999F9T) and an INN.
- [registry] ClinicalTrials.gov API v2, searched November 5, 2026: one record for davalintide / AC2307, NCT00785408 (a phase 2, randomized, double-blind, placebo-controlled dose-ranging study of subcutaneous AC2307 for body weight in 273 obese or overweight subjects, completed 2009). No results were posted and no journal paper reports it. https://clinicaltrials.gov/search?term=davalintide
Sources & Citations
The four studies carded above were read from their PubMed records on November 5, 2026. Structure, codes and identifiers come from the FDA Global Substance Registration System (UNII 668U999F9T) and ChEMBL (CHEMBL2105635); the absence of approval from Drugs@FDA and openFDA, and the single completed-but-unpublished phase 2 trial from ClinicalTrials.gov, all checked the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.